![]() |
||||||
|
![]() | Fusion Gene Summary |
![]() | Fusion Gene ORF analysis |
![]() | Fusion Genomic Features |
![]() | Fusion Protein Features |
![]() | Fusion Gene Sequence |
![]() | Fusion Gene PPI analysis |
![]() | Related Drugs |
![]() | Related Diseases |
Fusion gene:BCR-PDGFRA (FusionGDB2 ID:HG613TG5156) |
Fusion Gene Summary for BCR-PDGFRA |
![]() |
Fusion gene information | Fusion gene name: BCR-PDGFRA | Fusion gene ID: hg613tg5156 | Hgene | Tgene | Gene symbol | BCR | PDGFRA | Gene ID | 613 | 5156 |
Gene name | BCR activator of RhoGEF and GTPase | platelet derived growth factor receptor alpha | |
Synonyms | ALL|BCR1|CML|D22S11|D22S662|PHL | CD140A|PDGFR-2|PDGFR2 | |
Cytomap | ('BCR')('PDGFRA') 22q11.23 | 4q12 | |
Type of gene | protein-coding | protein-coding | |
Description | breakpoint cluster region proteinBCR, RhoGEF and GTPase activating proteinBCR/FGFR1 chimera proteinFGFR1/BCR chimera proteinbreakpoint cluster regionrenal carcinoma antigen NY-REN-26 | platelet-derived growth factor receptor alphaCD140 antigen-like family member ACD140a antigenPDGF-R-alphaalpha-type platelet-derived growth factor receptorplatelet-derived growth factor receptor 2platelet-derived growth factor receptor, alpha polype | |
Modification date | 20200313 | 20200329 | |
UniProtAcc | P11274 | P16234 | |
Ensembl transtripts involved in fusion gene | ENST00000436990, ENST00000305877, ENST00000359540, ENST00000398512, | ||
Fusion gene scores | * DoF score | 22 X 142 X 16=49984 | 18 X 27 X 8=3888 |
# samples | 163 | 17 | |
** MAII score | log2(163/49984*10)=-4.93852248902354 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(17/3888*10)=-4.51542156746808 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context | PubMed: BCR [Title/Abstract] AND PDGFRA [Title/Abstract] AND fusion [Title/Abstract] | ||
Most frequent breakpoint | BCR(23652041)-PDGFRA(55141056), # samples:2 | ||
Anticipated loss of major functional domain due to fusion event. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
![]() |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | BCR | GO:0090630 | activation of GTPase activity | 7479768 |
Tgene | PDGFRA | GO:0008284 | positive regulation of cell proliferation | 10806482 |
Tgene | PDGFRA | GO:0010544 | negative regulation of platelet activation | 8188664 |
Tgene | PDGFRA | GO:0018108 | peptidyl-tyrosine phosphorylation | 1646396|2536956|8188664 |
Tgene | PDGFRA | GO:0030335 | positive regulation of cell migration | 17470632 |
Tgene | PDGFRA | GO:0034614 | cellular response to reactive oxygen species | 24190966 |
Tgene | PDGFRA | GO:0038091 | positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway | 17470632 |
Tgene | PDGFRA | GO:0046777 | protein autophosphorylation | 1646396|2536956|8188664 |
Tgene | PDGFRA | GO:0048008 | platelet-derived growth factor receptor signaling pathway | 2536956|10806482 |
Tgene | PDGFRA | GO:0048146 | positive regulation of fibroblast proliferation | 10806482 |
![]() * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
ChimerDB4 | chronic myeloproliferative disorders | AY303970 | BCR | chr22 | 23652041 | PDGFRA | chr4 | 55141056 | ||
ChimerKB3 | . | . | BCR | chr22 | 23615320 | + | PDGFRA | chr4 | 55141007 | + |
Top |
Fusion Gene ORF analysis for BCR-PDGFRA |
![]() * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
3UTR-3CDS | ENST00000436990 | ENST00000257290 | BCR | chr22 | 23652041 | PDGFRA | chr4 | 55141056 | ||
3UTR-intron | ENST00000436990 | ENST00000508170 | BCR | chr22 | 23652041 | PDGFRA | chr4 | 55141056 | ||
5CDS-intron | ENST00000305877 | ENST00000508170 | BCR | chr22 | 23615320 | + | PDGFRA | chr4 | 55141007 | + |
5CDS-intron | ENST00000359540 | ENST00000508170 | BCR | chr22 | 23615320 | + | PDGFRA | chr4 | 55141007 | + |
In-frame | ENST00000305877 | ENST00000257290 | BCR | chr22 | 23615320 | + | PDGFRA | chr4 | 55141007 | + |
In-frame | ENST00000359540 | ENST00000257290 | BCR | chr22 | 23615320 | + | PDGFRA | chr4 | 55141007 | + |
intron-3CDS | ENST00000305877 | ENST00000257290 | BCR | chr22 | 23652041 | PDGFRA | chr4 | 55141056 | ||
intron-3CDS | ENST00000359540 | ENST00000257290 | BCR | chr22 | 23652041 | PDGFRA | chr4 | 55141056 | ||
intron-3CDS | ENST00000398512 | ENST00000257290 | BCR | chr22 | 23652041 | PDGFRA | chr4 | 55141056 | ||
intron-3CDS | ENST00000398512 | ENST00000257290 | BCR | chr22 | 23615320 | + | PDGFRA | chr4 | 55141007 | + |
intron-3CDS | ENST00000436990 | ENST00000257290 | BCR | chr22 | 23615320 | + | PDGFRA | chr4 | 55141007 | + |
intron-intron | ENST00000305877 | ENST00000508170 | BCR | chr22 | 23652041 | PDGFRA | chr4 | 55141056 | ||
intron-intron | ENST00000359540 | ENST00000508170 | BCR | chr22 | 23652041 | PDGFRA | chr4 | 55141056 | ||
intron-intron | ENST00000398512 | ENST00000508170 | BCR | chr22 | 23652041 | PDGFRA | chr4 | 55141056 | ||
intron-intron | ENST00000398512 | ENST00000508170 | BCR | chr22 | 23615320 | + | PDGFRA | chr4 | 55141007 | + |
intron-intron | ENST00000436990 | ENST00000508170 | BCR | chr22 | 23615320 | + | PDGFRA | chr4 | 55141007 | + |
![]() |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
ENST00000305877 | BCR | chr22 | 23615320 | + | ENST00000257290 | PDGFRA | chr4 | 55141007 | + | 7317 | 2725 | 751 | 4341 | 1196 |
ENST00000359540 | BCR | chr22 | 23615320 | + | ENST00000257290 | PDGFRA | chr4 | 55141007 | + | 7162 | 2570 | 596 | 4186 | 1196 |
![]() |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
Top |
Fusion Genomic Features for BCR-PDGFRA |
![]() |
Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
Top |
Fusion Protein Features for BCR-PDGFRA |
![]() Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr22:23652041/chr4:55141056) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
![]() |
![]() |
Hgene | Tgene |
BCR | PDGFRA |
FUNCTION: Protein with a unique structure having two opposing regulatory activities toward small GTP-binding proteins. The C-terminus is a GTPase-activating protein (GAP) domain which stimulates GTP hydrolysis by RAC1, RAC2 and CDC42. Accelerates the intrinsic rate of GTP hydrolysis of RAC1 or CDC42, leading to down-regulation of the active GTP-bound form (PubMed:7479768, PubMed:1903516, PubMed:17116687). The central Dbl homology (DH) domain functions as guanine nucleotide exchange factor (GEF) that modulates the GTPases CDC42, RHOA and RAC1. Promotes the conversion of CDC42, RHOA and RAC1 from the GDP-bound to the GTP-bound form (PubMed:7479768, PubMed:23940119). The amino terminus contains an intrinsic kinase activity (PubMed:1657398). Functions as an important negative regulator of neuronal RAC1 activity (By similarity). Regulates macrophage functions such as CSF1-directed motility and phagocytosis through the modulation of RAC1 activity (PubMed:17116687). Plays a major role as a RHOA GEF in keratinocytes being involved in focal adhesion formation and keratinocyte differentiation (PubMed:23940119). {ECO:0000250|UniProtKB:Q6PAJ1, ECO:0000269|PubMed:1657398, ECO:0000269|PubMed:17116687, ECO:0000269|PubMed:1903516, ECO:0000269|PubMed:23940119, ECO:0000269|PubMed:7479768}. | FUNCTION: Tyrosine-protein kinase that acts as a cell-surface receptor for PDGFA, PDGFB and PDGFC and plays an essential role in the regulation of embryonic development, cell proliferation, survival and chemotaxis. Depending on the context, promotes or inhibits cell proliferation and cell migration. Plays an important role in the differentiation of bone marrow-derived mesenchymal stem cells. Required for normal skeleton development and cephalic closure during embryonic development. Required for normal development of the mucosa lining the gastrointestinal tract, and for recruitment of mesenchymal cells and normal development of intestinal villi. Plays a role in cell migration and chemotaxis in wound healing. Plays a role in platelet activation, secretion of agonists from platelet granules, and in thrombin-induced platelet aggregation. Binding of its cognate ligands - homodimeric PDGFA, homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or homodimeric PDGFC -leads to the activation of several signaling cascades; the response depends on the nature of the bound ligand and is modulated by the formation of heterodimers between PDGFRA and PDGFRB. Phosphorylates PIK3R1, PLCG1, and PTPN11. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate, mobilization of cytosolic Ca(2+) and the activation of protein kinase C. Phosphorylates PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, and thereby mediates activation of the AKT1 signaling pathway. Mediates activation of HRAS and of the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. Promotes activation of STAT family members STAT1, STAT3 and STAT5A and/or STAT5B. Receptor signaling is down-regulated by protein phosphatases that dephosphorylate the receptor and its down-stream effectors, and by rapid internalization of the activated receptor. {ECO:0000269|PubMed:10734113, ECO:0000269|PubMed:10947961, ECO:0000269|PubMed:11297552, ECO:0000269|PubMed:12522257, ECO:0000269|PubMed:1646396, ECO:0000269|PubMed:17087943, ECO:0000269|PubMed:1709159, ECO:0000269|PubMed:17141222, ECO:0000269|PubMed:20972453, ECO:0000269|PubMed:21224473, ECO:0000269|PubMed:21596750, ECO:0000269|PubMed:2554309, ECO:0000269|PubMed:8188664, ECO:0000269|PubMed:8760137, ECO:0000269|PubMed:8943348}. |
![]() * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Gene Sequence for BCR-PDGFRA |
![]() |
>9530_9530_1_BCR-PDGFRA_BCR_chr22_23615320_ENST00000305877_PDGFRA_chr4_55141007_ENST00000257290_length(transcript)=7317nt_BP=2725nt TTCCAGGACTGCAGAACTGGCCCAGACCTCTGTATTGGAAAGGTCTTTATGGACCAGGGAGTCCGGTGTCTTTTTTACGGGGGACCCCTG GGCTGCGAGTTGCACAGTCCAATTCGCTGTTGTTAGGGCCTCAGTTTCCCAAAAGGCACAGGGACGGGGGGAGGGTGGCGGCTCGATGGG GGAGCCGCCTCCAGGGGGCCCCCCCGCCCTGTGCCCACGGCGCGGCCCCTTTAAGAGGCCCGCCTGGCTCCGTCATCCGCGCCGCGGCCA CCTCCCCCCGGCCCTCCCCTTCCTGCGGCGCAGAGTGCGGGCCGGGCGGGAGTGCGGCGAGAGCCGGCTGGCTGAGCTTAGCGTCCGAGG AGGCGGCGGCGGCGGCGGCGGCACGGCGGCGGCGGGGCTGTGGGGCGGTGCGGAAGCGAGAGGCGAGGAGCGCGCGGGCCGTGGCCAGAG TCTGGCGGCGGCCTGGCGGAGCGGAGAGCAGCGCCCGCGCCTCGCCGTGCGGAGGAGCCCCGCACACAATAGCGGCGCGCGCAGCCCGCG CCCTTCCCCCCGGCGCGCCCCGCCCCGCGCGCCGAGCGCCCCGCTCCGCCTCACCTGCCACCAGGGAGTGGGCGGGCATTGTTCGCCGCC GCCGCCGCCGCGCGGGCCATGGGGGCCGCCCGGCGCCCGGGGCCGGGCTGGCGAGGCGCCGCGCCGCCGCTGAGACGGGCCCCGCGCGCA GCCCGGCGGCGCAGGTAAGGCCGGCCGCGCCATGGTGGACCCGGTGGGCTTCGCGGAGGCGTGGAAGGCGCAGTTCCCGGACTCAGAGCC CCCGCGCATGGAGCTGCGCTCAGTGGGCGACATCGAGCAGGAGCTGGAGCGCTGCAAGGCCTCCATTCGGCGCCTGGAGCAGGAGGTGAA CCAGGAGCGCTTCCGCATGATCTACCTGCAGACGTTGCTGGCCAAGGAAAAGAAGAGCTATGACCGGCAGCGATGGGGCTTCCGGCGCGC GGCGCAGGCCCCCGACGGCGCCTCCGAGCCCCGAGCGTCCGCGTCGCGCCCGCAGCCAGCGCCCGCCGACGGAGCCGACCCGCCGCCCGC CGAGGAGCCCGAGGCCCGGCCCGACGGCGAGGGTTCTCCGGGTAAGGCCAGGCCCGGGACCGCCCGCAGGCCCGGGGCAGCCGCGTCGGG GGAACGGGACGACCGGGGACCCCCCGCCAGCGTGGCGGCGCTCAGGTCCAACTTCGAGCGGATCCGCAAGGGCCATGGCCAGCCCGGGGC GGACGCCGAGAAGCCCTTCTACGTGAACGTCGAGTTTCACCACGAGCGCGGCCTGGTGAAGGTCAACGACAAAGAGGTGTCGGACCGCAT CAGCTCCCTGGGCAGCCAGGCCATGCAGATGGAGCGCAAAAAGTCCCAGCACGGCGCGGGCTCGAGCGTGGGGGATGCATCCAGGCCCCC TTACCGGGGACGCTCCTCGGAGAGCAGCTGCGGCGTCGACGGCGACTACGAGGACGCCGAGTTGAACCCCCGCTTCCTGAAGGACAACCT GATCGACGCCAATGGCGGTAGCAGGCCCCCTTGGCCGCCCCTGGAGTACCAGCCCTACCAGAGCATCTACGTCGGGGGCATGATGGAAGG GGAGGGCAAGGGCCCGCTCCTGCGCAGCCAGAGCACCTCTGAGCAGGAGAAGCGCCTTACCTGGCCCCGCAGGTCCTACTCCCCCCGGAG TTTTGAGGATTGCGGAGGCGGCTATACCCCGGACTGCAGCTCCAATGAGAACCTCACCTCCAGCGAGGAGGACTTCTCCTCTGGCCAGTC CAGCCGCGTGTCCCCAAGCCCCACCACCTACCGCATGTTCCGGGACAAAAGCCGCTCTCCCTCGCAGAACTCGCAACAGTCCTTCGACAG CAGCAGTCCCCCCACGCCGCAGTGCCATAAGCGGCACCGGCACTGCCCGGTTGTCGTGTCCGAGGCCACCATCGTGGGCGTCCGCAAGAC CGGGCAGATCTGGCCCAACGATGGCGAGGGCGCCTTCCATGGAGACGCAGATGGCTCGTTCGGAACACCACCTGGATACGGCTGCGCTGC AGACCGGGCAGAGGAGCAGCGCCGGCACCAAGATGGGCTGCCCTACATTGATGACTCGCCCTCCTCATCGCCCCACCTCAGCAGCAAGGG CAGGGGCAGCCGGGATGCGCTGGTCTCGGGAGCCCTGGAGTCCACTAAAGCGAGTGAGCTGGACTTGGAAAAGGGCTTGGAGATGAGAAA ATGGGTCCTGTCGGGAATCCTGGCTAGCGAGGAGACTTACCTGAGCCACCTGGAGGCACTGCTGCTGCCCATGAAGCCTTTGAAAGCCGC TGCCACCACCTCTCAGCCGGTGCTGACGAGTCAGCAGATCGAGACCATCTTCTTCAAAGTGCCTGAGCTCTACGAGATCCACAAGGAGTT CTATGATGGGCTCTTCCCCCGCGTGCAGCAGTGGAGCCACCAGCAGCGGGTGGGCGACCTCTTCCAGAAGCTGGCCAGCCAGCTGGGTGT GTACCGGGCCTTCGTGGACAACTACGGAGTTGCCATGGAAATGGCTGAGAAGTGCTGTCAGGCCAATGCTCAGTTTGCAGAAATCTCCGA GAACCTGAGAGCCAGAAGCAACAAAGATGCCAAGGATCCAACGACCAAGAACTCTCTGGAAACTCTGCTCTACAAGCCTGTGGACCGTGT GACGAGGAGCACGCTGGTCCTCCATAAACCGAGGTATGAAATTCGCTGGAGGGTCATTGAATCAATCAGCCCAGATGGACATGAATATAT TTATGTGGACCCGATGCAGCTGCCTTATGACTCAAGATGGGAGTTTCCAAGAGATGGACTAGTGCTTGGTCGGGTCTTGGGGTCTGGAGC GTTTGGGAAGGTGGTTGAAGGAACAGCCTATGGATTAAGCCGGTCCCAACCTGTCATGAAAGTTGCAGTGAAGATGCTAAAACCCACGGC CAGATCCAGTGAAAAACAAGCTCTCATGTCTGAACTGAAGATAATGACTCACCTGGGGCCACATTTGAACATTGTAAACTTGCTGGGAGC CTGCACCAAGTCAGGCCCCATTTACATCATCACAGAGTATTGCTTCTATGGAGATTTGGTCAACTATTTGCATAAGAATAGGGATAGCTT CCTGAGCCACCACCCAGAGAAGCCAAAGAAAGAGCTGGATATCTTTGGATTGAACCCTGCTGATGAAAGCACACGGAGCTATGTTATTTT ATCTTTTGAAAACAATGGTGACTACATGGACATGAAGCAGGCTGATACTACACAGTATGTCCCCATGCTAGAAAGGAAAGAGGTTTCTAA ATATTCCGACATCCAGAGATCACTCTATGATCGTCCAGCCTCATATAAGAAGAAATCTATGTTAGACTCAGAAGTCAAAAACCTCCTTTC AGATGATAACTCAGAAGGCCTTACTTTATTGGATTTGTTGAGCTTCACCTATCAAGTTGCCCGAGGAATGGAGTTTTTGGCTTCAAAAAA TTGTGTCCACCGTGATCTGGCTGCTCGCAACGTCCTCCTGGCACAAGGAAAAATTGTGAAGATCTGTGACTTTGGCCTGGCCAGAGACAT CATGCATGATTCGAACTATGTGTCGAAAGGCAGTACCTTTCTGCCCGTGAAGTGGATGGCTCCTGAGAGCATCTTTGACAACCTCTACAC CACACTGAGTGATGTCTGGTCTTATGGCATTCTGCTCTGGGAGATCTTTTCCCTTGGTGGCACCCCTTACCCCGGCATGATGGTGGATTC TACTTTCTACAATAAGATCAAGAGTGGGTACCGGATGGCCAAGCCTGACCACGCTACCAGTGAAGTCTACGAGATCATGGTGAAATGCTG GAACAGTGAGCCGGAGAAGAGACCCTCCTTTTACCACCTGAGTGAGATTGTGGAGAATCTGCTGCCTGGACAATATAAAAAGAGTTATGA AAAAATTCACCTGGACTTCCTGAAGAGTGACCATCCTGCTGTGGCACGCATGCGTGTGGACTCAGACAATGCATACATTGGTGTCACCTA CAAAAACGAGGAAGACAAGCTGAAGGACTGGGAGGGTGGTCTGGATGAGCAGAGACTGAGCGCTGACAGTGGCTACATCATTCCTCTGCC TGACATTGACCCTGTCCCTGAGGAGGAGGACCTGGGCAAGAGGAACAGACACAGCTCGCAGACCTCTGAAGAGAGTGCCATTGAGACGGG TTCCAGCAGTTCCACCTTCATCAAGAGAGAGGACGAGACCATTGAAGACATCGACATGATGGATGACATCGGCATAGACTCTTCAGACCT GGTGGAAGACAGCTTCCTGTAACTGGCGGATTCGAGGGGTTCCTTCCACTTCTGGGGCCACCTCTGGATCCCGTTCAGAAAACCACTTTA TTGCAATGCAGAGGTTGAGAGGAGGACTTGGTTGATGTTTAAAGAGAAGTTCCCAGCCAAGGGCCTCGGGGAGCGTTCTAAATATGAATG AATGGGATATTTTGAAATGAACTTTGTCAGTGTTGCCTCTTGCAATGCCTCAGTAGCATCTCAGTGGTGTGTGAAGTTTGGAGATAGATG GATAAGGGAATAATAGGCCACAGAAGGTGAACTTTGTGCTTCAAGGACATTGGTGAGAGTCCAACAGACACAATTTATACTGCGACAGAA CTTCAGCATTGTAATTATGTAAATAACTCTAACCAAGGCTGTGTTTAGATTGTATTAACTATCTTCTTTGGACTTCTGAAGAGACCACTC AATCCATCCATGTACTTCCCTCTTGAAACCTGATGTCAGCTGCTGTTGAACTTTTTAAAGAAGTGCATGAAAAACCATTTTTGAACCTTA AAAGGTACTGGTACTATAGCATTTTGCTATCTTTTTTAGTGTTAAAGAGATAAAGAATAATAATTAACCAACCTTGTTTAATAGATTTGG GTCATTTAGAAGCCTGACAACTCATTTTCATATTGTAATCTATGTTTATAATACTACTACTGTTATCAGTAATGCTAAATGTGTAATAAT GTAACATGATTTCCCTCCAGAGAAAGCACAATTTAAAACAATCCTTACTAAGTAGGTGATGAGTTTGACAGTTTTTGACATTTATATTAA ATAACATGTTTCTCTATAAAGTATGGTAATAGCTTTAGTGAATTAAATTTAGTTGAGCATAGAGAACAAAGTAAAAGTAGTGTTGTCCAG GAAGTCAGAATTTTTAACTGTACTGAATAGGTTCCCCAATCCATCGTATTAAAAAACAATTAACTGCCCTCTGAAATAATGGGATTAGAA ACAAACAAAACTCTTAAGTCCTAAAAGTTCTCAATGTAGAGGCATAAACCTGTGCTGAACATAACTTCTCATGTATATTACCCAATGGAA AATATAATGATCAGCAAAAAGACTGGATTTGCAGAAGTTTTTTTTTTTTTTTTCTTCATGCCTGATGAAAGCTTTGGCGACCCCAATATA TGTATTTTTTGAATCTATGAACCTGAAAAGGGTCAGAAGGATGCCCAGACATCAGCCTCCTTCTTTCACCCCTTACCCCAAAGAGAAAGA GTTTGAAACTCGAGACCATAAAGATATTCTTTAGTGGAGGCTGGATGTGCATTAGCCTGGATCCTCAGTTCTCAAATGTGTGTGGCAGCC AGGATGACTAGATCCTGGGTTTCCATCCTTGAGATTCTGAAGTATGAAGTCTGAGGGAAACCAGAGTCTGTATTTTTCTAAACTCCCTGG CTGTTCTGATCGGCCAGTTTTCGGAAACACTGACTTAGGTTTCAGGAAGTTGCCATGGGAAACAAATAATTTGAACTTTGGAACAGGGTT GGCATTCAACCACGCAGGAAGCCTACTATTTAAATCCTTGGCTTCAGGTTAGTGACATTTAATGCCATCTAGCTAGCAATTGCGACCTTA ATTTAACTTTCCAGTCTTAGCTGAGGCTGAGAAAGCTAAAGTTTGGTTTTGACAGGTTTTCCAAAAGTAAAGATGCTACTTCCCACTGTA TGGGGGAGATTGAACTTTCCCCGTCTCCCGTCTTCTGCCTCCCACTCCATACCCCGCCAAGGAAAGGCATGTACAAAAATTATGCAATTC AGTGTTCCAAGTCTCTGTGTAACCAGCTCAGTGTTTTGGTGGAAAAAACATTTTAAGTTTTACTGATAATTTGAGGTTAGATGGGAGGAT GAATTGTCACATCTATCCACACTGTCAAACAGGTTGGTGTGGGTTCATTGGCATTCTTTGCAATACTGCTTAATTGCTGATACCATATGA ATGAAACATGGGCTGTGATTACTGCAATCACTGTGCTATCGGCAGATGATGCTTTGGAAGATGCAGAAGCAATAATAAAGTACTTGACTA CCTACTGGTGTAATCTCAATGCAAGCCCCAACTTTCTTATCCAACTTTTTCATAGTAAGTGCGAAGACTGAGCCAGATTGGCCAATTAAA AACGAAAACCTGACTAGGTTCTGTAGAGCCAATTAGACTTGAAATACGTTTGTGTTTCTAGAATCACAGCTCAAGCATTCTGTTTATCGC TCACTCTCCCTTGTACAGCCTTATTTTGTTGGTGCTTTGCATTTTGATATTGCTGTGAGCCTTGCATGACATCATGAGGCCGGATGAAAC TTCTCAGTCCAGCAGTTTCCAGTCCTAACAAATGCTCCCACCTGAATTTGTATATGACTGCATTTGTGTGTGTGTGTGTGTTTTCAGCAA ATTCCAGATTTGTTTCCTTTTGGCCTCCTGCAAAGTCTCCAGAAGAAAATTTGCCAATCTTTCCTACTTTCTATTTTTATGATGACAATC AAAGCCGGCCTGAGAAACACTATTTGTGACTTTTTAAACGATTAGTGATGTCCTTAAAATGTGGTCTGCCAATCTGTACAAAATGGTCCT ATTTTTGTGAAGAGGGACATAAGATAAAATGATGTTATACATCAATATGTATATATGTATTTCTATATAGACTTGGAGAATACTGCCAAA ACATTTATGACAAGCTGTATCACTGCCTTCGTTTATATTTTTTTAACTGTGATAATCCCCACAGGCACATTAACTGTTGCACTTTTGAAT GTCCAAAATTTATATTTTAGAAATAATAAAAAGAAAGATACTTACATGTTCCCAAAACAATGGTGTGGTGAATGTGTGAGAAAAACTAAC TTGATAGGGTCTACCAATACAAAATGTATTACGAATGCCCCTGTTCATGTTTTTGTTTTAAAACGTGTAAATGAAGATCTTTATATTTCA >9530_9530_1_BCR-PDGFRA_BCR_chr22_23615320_ENST00000305877_PDGFRA_chr4_55141007_ENST00000257290_length(amino acids)=1196AA_BP=656 MVDPVGFAEAWKAQFPDSEPPRMELRSVGDIEQELERCKASIRRLEQEVNQERFRMIYLQTLLAKEKKSYDRQRWGFRRAAQAPDGASEP RASASRPQPAPADGADPPPAEEPEARPDGEGSPGKARPGTARRPGAAASGERDDRGPPASVAALRSNFERIRKGHGQPGADAEKPFYVNV EFHHERGLVKVNDKEVSDRISSLGSQAMQMERKKSQHGAGSSVGDASRPPYRGRSSESSCGVDGDYEDAELNPRFLKDNLIDANGGSRPP WPPLEYQPYQSIYVGGMMEGEGKGPLLRSQSTSEQEKRLTWPRRSYSPRSFEDCGGGYTPDCSSNENLTSSEEDFSSGQSSRVSPSPTTY RMFRDKSRSPSQNSQQSFDSSSPPTPQCHKRHRHCPVVVSEATIVGVRKTGQIWPNDGEGAFHGDADGSFGTPPGYGCAADRAEEQRRHQ DGLPYIDDSPSSSPHLSSKGRGSRDALVSGALESTKASELDLEKGLEMRKWVLSGILASEETYLSHLEALLLPMKPLKAAATTSQPVLTS QQIETIFFKVPELYEIHKEFYDGLFPRVQQWSHQQRVGDLFQKLASQLGVYRAFVDNYGVAMEMAEKCCQANAQFAEISENLRARSNKDA KDPTTKNSLETLLYKPVDRVTRSTLVLHKPRYEIRWRVIESISPDGHEYIYVDPMQLPYDSRWEFPRDGLVLGRVLGSGAFGKVVEGTAY GLSRSQPVMKVAVKMLKPTARSSEKQALMSELKIMTHLGPHLNIVNLLGACTKSGPIYIITEYCFYGDLVNYLHKNRDSFLSHHPEKPKK ELDIFGLNPADESTRSYVILSFENNGDYMDMKQADTTQYVPMLERKEVSKYSDIQRSLYDRPASYKKKSMLDSEVKNLLSDDNSEGLTLL DLLSFTYQVARGMEFLASKNCVHRDLAARNVLLAQGKIVKICDFGLARDIMHDSNYVSKGSTFLPVKWMAPESIFDNLYTTLSDVWSYGI LLWEIFSLGGTPYPGMMVDSTFYNKIKSGYRMAKPDHATSEVYEIMVKCWNSEPEKRPSFYHLSEIVENLLPGQYKKSYEKIHLDFLKSD HPAVARMRVDSDNAYIGVTYKNEEDKLKDWEGGLDEQRLSADSGYIIPLPDIDPVPEEEDLGKRNRHSSQTSEESAIETGSSSSTFIKRE -------------------------------------------------------------- >9530_9530_2_BCR-PDGFRA_BCR_chr22_23615320_ENST00000359540_PDGFRA_chr4_55141007_ENST00000257290_length(transcript)=7162nt_BP=2570nt GGGGGGAGGGTGGCGGCTCGATGGGGGAGCCGCCTCCAGGGGGCCCCCCCGCCCTGTGCCCACGGCGCGGCCCCTTTAAGAGGCCCGCCT GGCTCCGTCATCCGCGCCGCGGCCACCTCCCCCCGGCCCTCCCCTTCCTGCGGCGCAGAGTGCGGGCCGGGCGGGAGTGCGGCGAGAGCC GGCTGGCTGAGCTTAGCGTCCGAGGAGGCGGCGGCGGCGGCGGCGGCACGGCGGCGGCGGGGCTGTGGGGCGGTGCGGAAGCGAGAGGCG AGGAGCGCGCGGGCCGTGGCCAGAGTCTGGCGGCGGCCTGGCGGAGCGGAGAGCAGCGCCCGCGCCTCGCCGTGCGGAGGAGCCCCGCAC ACAATAGCGGCGCGCGCAGCCCGCGCCCTTCCCCCCGGCGCGCCCCGCCCCGCGCGCCGAGCGCCCCGCTCCGCCTCACCTGCCACCAGG GAGTGGGCGGGCATTGTTCGCCGCCGCCGCCGCCGCGCGGGCCATGGGGGCCGCCCGGCGCCCGGGGCCGGGCTGGCGAGGCGCCGCGCC GCCGCTGAGACGGGCCCCGCGCGCAGCCCGGCGGCGCAGGTAAGGCCGGCCGCGCCATGGTGGACCCGGTGGGCTTCGCGGAGGCGTGGA AGGCGCAGTTCCCGGACTCAGAGCCCCCGCGCATGGAGCTGCGCTCAGTGGGCGACATCGAGCAGGAGCTGGAGCGCTGCAAGGCCTCCA TTCGGCGCCTGGAGCAGGAGGTGAACCAGGAGCGCTTCCGCATGATCTACCTGCAGACGTTGCTGGCCAAGGAAAAGAAGAGCTATGACC GGCAGCGATGGGGCTTCCGGCGCGCGGCGCAGGCCCCCGACGGCGCCTCCGAGCCCCGAGCGTCCGCGTCGCGCCCGCAGCCAGCGCCCG CCGACGGAGCCGACCCGCCGCCCGCCGAGGAGCCCGAGGCCCGGCCCGACGGCGAGGGTTCTCCGGGTAAGGCCAGGCCCGGGACCGCCC GCAGGCCCGGGGCAGCCGCGTCGGGGGAACGGGACGACCGGGGACCCCCCGCCAGCGTGGCGGCGCTCAGGTCCAACTTCGAGCGGATCC GCAAGGGCCATGGCCAGCCCGGGGCGGACGCCGAGAAGCCCTTCTACGTGAACGTCGAGTTTCACCACGAGCGCGGCCTGGTGAAGGTCA ACGACAAAGAGGTGTCGGACCGCATCAGCTCCCTGGGCAGCCAGGCCATGCAGATGGAGCGCAAAAAGTCCCAGCACGGCGCGGGCTCGA GCGTGGGGGATGCATCCAGGCCCCCTTACCGGGGACGCTCCTCGGAGAGCAGCTGCGGCGTCGACGGCGACTACGAGGACGCCGAGTTGA ACCCCCGCTTCCTGAAGGACAACCTGATCGACGCCAATGGCGGTAGCAGGCCCCCTTGGCCGCCCCTGGAGTACCAGCCCTACCAGAGCA TCTACGTCGGGGGCATGATGGAAGGGGAGGGCAAGGGCCCGCTCCTGCGCAGCCAGAGCACCTCTGAGCAGGAGAAGCGCCTTACCTGGC CCCGCAGGTCCTACTCCCCCCGGAGTTTTGAGGATTGCGGAGGCGGCTATACCCCGGACTGCAGCTCCAATGAGAACCTCACCTCCAGCG AGGAGGACTTCTCCTCTGGCCAGTCCAGCCGCGTGTCCCCAAGCCCCACCACCTACCGCATGTTCCGGGACAAAAGCCGCTCTCCCTCGC AGAACTCGCAACAGTCCTTCGACAGCAGCAGTCCCCCCACGCCGCAGTGCCATAAGCGGCACCGGCACTGCCCGGTTGTCGTGTCCGAGG CCACCATCGTGGGCGTCCGCAAGACCGGGCAGATCTGGCCCAACGATGGCGAGGGCGCCTTCCATGGAGACGCAGATGGCTCGTTCGGAA CACCACCTGGATACGGCTGCGCTGCAGACCGGGCAGAGGAGCAGCGCCGGCACCAAGATGGGCTGCCCTACATTGATGACTCGCCCTCCT CATCGCCCCACCTCAGCAGCAAGGGCAGGGGCAGCCGGGATGCGCTGGTCTCGGGAGCCCTGGAGTCCACTAAAGCGAGTGAGCTGGACT TGGAAAAGGGCTTGGAGATGAGAAAATGGGTCCTGTCGGGAATCCTGGCTAGCGAGGAGACTTACCTGAGCCACCTGGAGGCACTGCTGC TGCCCATGAAGCCTTTGAAAGCCGCTGCCACCACCTCTCAGCCGGTGCTGACGAGTCAGCAGATCGAGACCATCTTCTTCAAAGTGCCTG AGCTCTACGAGATCCACAAGGAGTTCTATGATGGGCTCTTCCCCCGCGTGCAGCAGTGGAGCCACCAGCAGCGGGTGGGCGACCTCTTCC AGAAGCTGGCCAGCCAGCTGGGTGTGTACCGGGCCTTCGTGGACAACTACGGAGTTGCCATGGAAATGGCTGAGAAGTGCTGTCAGGCCA ATGCTCAGTTTGCAGAAATCTCCGAGAACCTGAGAGCCAGAAGCAACAAAGATGCCAAGGATCCAACGACCAAGAACTCTCTGGAAACTC TGCTCTACAAGCCTGTGGACCGTGTGACGAGGAGCACGCTGGTCCTCCATAAACCGAGGTATGAAATTCGCTGGAGGGTCATTGAATCAA TCAGCCCAGATGGACATGAATATATTTATGTGGACCCGATGCAGCTGCCTTATGACTCAAGATGGGAGTTTCCAAGAGATGGACTAGTGC TTGGTCGGGTCTTGGGGTCTGGAGCGTTTGGGAAGGTGGTTGAAGGAACAGCCTATGGATTAAGCCGGTCCCAACCTGTCATGAAAGTTG CAGTGAAGATGCTAAAACCCACGGCCAGATCCAGTGAAAAACAAGCTCTCATGTCTGAACTGAAGATAATGACTCACCTGGGGCCACATT TGAACATTGTAAACTTGCTGGGAGCCTGCACCAAGTCAGGCCCCATTTACATCATCACAGAGTATTGCTTCTATGGAGATTTGGTCAACT ATTTGCATAAGAATAGGGATAGCTTCCTGAGCCACCACCCAGAGAAGCCAAAGAAAGAGCTGGATATCTTTGGATTGAACCCTGCTGATG AAAGCACACGGAGCTATGTTATTTTATCTTTTGAAAACAATGGTGACTACATGGACATGAAGCAGGCTGATACTACACAGTATGTCCCCA TGCTAGAAAGGAAAGAGGTTTCTAAATATTCCGACATCCAGAGATCACTCTATGATCGTCCAGCCTCATATAAGAAGAAATCTATGTTAG ACTCAGAAGTCAAAAACCTCCTTTCAGATGATAACTCAGAAGGCCTTACTTTATTGGATTTGTTGAGCTTCACCTATCAAGTTGCCCGAG GAATGGAGTTTTTGGCTTCAAAAAATTGTGTCCACCGTGATCTGGCTGCTCGCAACGTCCTCCTGGCACAAGGAAAAATTGTGAAGATCT GTGACTTTGGCCTGGCCAGAGACATCATGCATGATTCGAACTATGTGTCGAAAGGCAGTACCTTTCTGCCCGTGAAGTGGATGGCTCCTG AGAGCATCTTTGACAACCTCTACACCACACTGAGTGATGTCTGGTCTTATGGCATTCTGCTCTGGGAGATCTTTTCCCTTGGTGGCACCC CTTACCCCGGCATGATGGTGGATTCTACTTTCTACAATAAGATCAAGAGTGGGTACCGGATGGCCAAGCCTGACCACGCTACCAGTGAAG TCTACGAGATCATGGTGAAATGCTGGAACAGTGAGCCGGAGAAGAGACCCTCCTTTTACCACCTGAGTGAGATTGTGGAGAATCTGCTGC CTGGACAATATAAAAAGAGTTATGAAAAAATTCACCTGGACTTCCTGAAGAGTGACCATCCTGCTGTGGCACGCATGCGTGTGGACTCAG ACAATGCATACATTGGTGTCACCTACAAAAACGAGGAAGACAAGCTGAAGGACTGGGAGGGTGGTCTGGATGAGCAGAGACTGAGCGCTG ACAGTGGCTACATCATTCCTCTGCCTGACATTGACCCTGTCCCTGAGGAGGAGGACCTGGGCAAGAGGAACAGACACAGCTCGCAGACCT CTGAAGAGAGTGCCATTGAGACGGGTTCCAGCAGTTCCACCTTCATCAAGAGAGAGGACGAGACCATTGAAGACATCGACATGATGGATG ACATCGGCATAGACTCTTCAGACCTGGTGGAAGACAGCTTCCTGTAACTGGCGGATTCGAGGGGTTCCTTCCACTTCTGGGGCCACCTCT GGATCCCGTTCAGAAAACCACTTTATTGCAATGCAGAGGTTGAGAGGAGGACTTGGTTGATGTTTAAAGAGAAGTTCCCAGCCAAGGGCC TCGGGGAGCGTTCTAAATATGAATGAATGGGATATTTTGAAATGAACTTTGTCAGTGTTGCCTCTTGCAATGCCTCAGTAGCATCTCAGT GGTGTGTGAAGTTTGGAGATAGATGGATAAGGGAATAATAGGCCACAGAAGGTGAACTTTGTGCTTCAAGGACATTGGTGAGAGTCCAAC AGACACAATTTATACTGCGACAGAACTTCAGCATTGTAATTATGTAAATAACTCTAACCAAGGCTGTGTTTAGATTGTATTAACTATCTT CTTTGGACTTCTGAAGAGACCACTCAATCCATCCATGTACTTCCCTCTTGAAACCTGATGTCAGCTGCTGTTGAACTTTTTAAAGAAGTG CATGAAAAACCATTTTTGAACCTTAAAAGGTACTGGTACTATAGCATTTTGCTATCTTTTTTAGTGTTAAAGAGATAAAGAATAATAATT AACCAACCTTGTTTAATAGATTTGGGTCATTTAGAAGCCTGACAACTCATTTTCATATTGTAATCTATGTTTATAATACTACTACTGTTA TCAGTAATGCTAAATGTGTAATAATGTAACATGATTTCCCTCCAGAGAAAGCACAATTTAAAACAATCCTTACTAAGTAGGTGATGAGTT TGACAGTTTTTGACATTTATATTAAATAACATGTTTCTCTATAAAGTATGGTAATAGCTTTAGTGAATTAAATTTAGTTGAGCATAGAGA ACAAAGTAAAAGTAGTGTTGTCCAGGAAGTCAGAATTTTTAACTGTACTGAATAGGTTCCCCAATCCATCGTATTAAAAAACAATTAACT GCCCTCTGAAATAATGGGATTAGAAACAAACAAAACTCTTAAGTCCTAAAAGTTCTCAATGTAGAGGCATAAACCTGTGCTGAACATAAC TTCTCATGTATATTACCCAATGGAAAATATAATGATCAGCAAAAAGACTGGATTTGCAGAAGTTTTTTTTTTTTTTTTCTTCATGCCTGA TGAAAGCTTTGGCGACCCCAATATATGTATTTTTTGAATCTATGAACCTGAAAAGGGTCAGAAGGATGCCCAGACATCAGCCTCCTTCTT TCACCCCTTACCCCAAAGAGAAAGAGTTTGAAACTCGAGACCATAAAGATATTCTTTAGTGGAGGCTGGATGTGCATTAGCCTGGATCCT CAGTTCTCAAATGTGTGTGGCAGCCAGGATGACTAGATCCTGGGTTTCCATCCTTGAGATTCTGAAGTATGAAGTCTGAGGGAAACCAGA GTCTGTATTTTTCTAAACTCCCTGGCTGTTCTGATCGGCCAGTTTTCGGAAACACTGACTTAGGTTTCAGGAAGTTGCCATGGGAAACAA ATAATTTGAACTTTGGAACAGGGTTGGCATTCAACCACGCAGGAAGCCTACTATTTAAATCCTTGGCTTCAGGTTAGTGACATTTAATGC CATCTAGCTAGCAATTGCGACCTTAATTTAACTTTCCAGTCTTAGCTGAGGCTGAGAAAGCTAAAGTTTGGTTTTGACAGGTTTTCCAAA AGTAAAGATGCTACTTCCCACTGTATGGGGGAGATTGAACTTTCCCCGTCTCCCGTCTTCTGCCTCCCACTCCATACCCCGCCAAGGAAA GGCATGTACAAAAATTATGCAATTCAGTGTTCCAAGTCTCTGTGTAACCAGCTCAGTGTTTTGGTGGAAAAAACATTTTAAGTTTTACTG ATAATTTGAGGTTAGATGGGAGGATGAATTGTCACATCTATCCACACTGTCAAACAGGTTGGTGTGGGTTCATTGGCATTCTTTGCAATA CTGCTTAATTGCTGATACCATATGAATGAAACATGGGCTGTGATTACTGCAATCACTGTGCTATCGGCAGATGATGCTTTGGAAGATGCA GAAGCAATAATAAAGTACTTGACTACCTACTGGTGTAATCTCAATGCAAGCCCCAACTTTCTTATCCAACTTTTTCATAGTAAGTGCGAA GACTGAGCCAGATTGGCCAATTAAAAACGAAAACCTGACTAGGTTCTGTAGAGCCAATTAGACTTGAAATACGTTTGTGTTTCTAGAATC ACAGCTCAAGCATTCTGTTTATCGCTCACTCTCCCTTGTACAGCCTTATTTTGTTGGTGCTTTGCATTTTGATATTGCTGTGAGCCTTGC ATGACATCATGAGGCCGGATGAAACTTCTCAGTCCAGCAGTTTCCAGTCCTAACAAATGCTCCCACCTGAATTTGTATATGACTGCATTT GTGTGTGTGTGTGTGTTTTCAGCAAATTCCAGATTTGTTTCCTTTTGGCCTCCTGCAAAGTCTCCAGAAGAAAATTTGCCAATCTTTCCT ACTTTCTATTTTTATGATGACAATCAAAGCCGGCCTGAGAAACACTATTTGTGACTTTTTAAACGATTAGTGATGTCCTTAAAATGTGGT CTGCCAATCTGTACAAAATGGTCCTATTTTTGTGAAGAGGGACATAAGATAAAATGATGTTATACATCAATATGTATATATGTATTTCTA TATAGACTTGGAGAATACTGCCAAAACATTTATGACAAGCTGTATCACTGCCTTCGTTTATATTTTTTTAACTGTGATAATCCCCACAGG CACATTAACTGTTGCACTTTTGAATGTCCAAAATTTATATTTTAGAAATAATAAAAAGAAAGATACTTACATGTTCCCAAAACAATGGTG TGGTGAATGTGTGAGAAAAACTAACTTGATAGGGTCTACCAATACAAAATGTATTACGAATGCCCCTGTTCATGTTTTTGTTTTAAAACG >9530_9530_2_BCR-PDGFRA_BCR_chr22_23615320_ENST00000359540_PDGFRA_chr4_55141007_ENST00000257290_length(amino acids)=1196AA_BP=656 MVDPVGFAEAWKAQFPDSEPPRMELRSVGDIEQELERCKASIRRLEQEVNQERFRMIYLQTLLAKEKKSYDRQRWGFRRAAQAPDGASEP RASASRPQPAPADGADPPPAEEPEARPDGEGSPGKARPGTARRPGAAASGERDDRGPPASVAALRSNFERIRKGHGQPGADAEKPFYVNV EFHHERGLVKVNDKEVSDRISSLGSQAMQMERKKSQHGAGSSVGDASRPPYRGRSSESSCGVDGDYEDAELNPRFLKDNLIDANGGSRPP WPPLEYQPYQSIYVGGMMEGEGKGPLLRSQSTSEQEKRLTWPRRSYSPRSFEDCGGGYTPDCSSNENLTSSEEDFSSGQSSRVSPSPTTY RMFRDKSRSPSQNSQQSFDSSSPPTPQCHKRHRHCPVVVSEATIVGVRKTGQIWPNDGEGAFHGDADGSFGTPPGYGCAADRAEEQRRHQ DGLPYIDDSPSSSPHLSSKGRGSRDALVSGALESTKASELDLEKGLEMRKWVLSGILASEETYLSHLEALLLPMKPLKAAATTSQPVLTS QQIETIFFKVPELYEIHKEFYDGLFPRVQQWSHQQRVGDLFQKLASQLGVYRAFVDNYGVAMEMAEKCCQANAQFAEISENLRARSNKDA KDPTTKNSLETLLYKPVDRVTRSTLVLHKPRYEIRWRVIESISPDGHEYIYVDPMQLPYDSRWEFPRDGLVLGRVLGSGAFGKVVEGTAY GLSRSQPVMKVAVKMLKPTARSSEKQALMSELKIMTHLGPHLNIVNLLGACTKSGPIYIITEYCFYGDLVNYLHKNRDSFLSHHPEKPKK ELDIFGLNPADESTRSYVILSFENNGDYMDMKQADTTQYVPMLERKEVSKYSDIQRSLYDRPASYKKKSMLDSEVKNLLSDDNSEGLTLL DLLSFTYQVARGMEFLASKNCVHRDLAARNVLLAQGKIVKICDFGLARDIMHDSNYVSKGSTFLPVKWMAPESIFDNLYTTLSDVWSYGI LLWEIFSLGGTPYPGMMVDSTFYNKIKSGYRMAKPDHATSEVYEIMVKCWNSEPEKRPSFYHLSEIVENLLPGQYKKSYEKIHLDFLKSD HPAVARMRVDSDNAYIGVTYKNEEDKLKDWEGGLDEQRLSADSGYIIPLPDIDPVPEEEDLGKRNRHSSQTSEESAIETGSSSSTFIKRE -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for BCR-PDGFRA |
![]() |
![]() |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for BCR-PDGFRA |
![]() (DrugBank Version 5.1.8 2021-05-08) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Hgene | BCR | P11274 | DB00619 | Imatinib | Inhibitor | Small molecule | Approved |
Hgene | BCR | P11274 | DB00619 | Imatinib | Inhibitor | Small molecule | Approved |
Hgene | BCR | P11274 | DB00619 | Imatinib | Inhibitor | Small molecule | Approved |
Hgene | BCR | P11274 | DB06616 | Bosutinib | Inhibitor | Small molecule | Approved |
Hgene | BCR | P11274 | DB06616 | Bosutinib | Inhibitor | Small molecule | Approved |
Hgene | BCR | P11274 | DB06616 | Bosutinib | Inhibitor | Small molecule | Approved |
Hgene | BCR | P11274 | DB01254 | Dasatinib | Small molecule | Approved|Investigational | |
Hgene | BCR | P11274 | DB01254 | Dasatinib | Small molecule | Approved|Investigational | |
Hgene | BCR | P11274 | DB01254 | Dasatinib | Small molecule | Approved|Investigational | |
Hgene | BCR | P11274 | DB08901 | Ponatinib | Inhibitor | Small molecule | Approved|Investigational |
Hgene | BCR | P11274 | DB08901 | Ponatinib | Inhibitor | Small molecule | Approved|Investigational |
Hgene | BCR | P11274 | DB08901 | Ponatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | PDGFRA | P16234 | DB00619 | Imatinib | Antagonist | Small molecule | Approved |
Tgene | PDGFRA | P16234 | DB00619 | Imatinib | Antagonist | Small molecule | Approved |
Tgene | PDGFRA | P16234 | DB00619 | Imatinib | Antagonist | Small molecule | Approved |
Tgene | PDGFRA | P16234 | DB06589 | Pazopanib | Inhibitor | Small molecule | Approved |
Tgene | PDGFRA | P16234 | DB06589 | Pazopanib | Inhibitor | Small molecule | Approved |
Tgene | PDGFRA | P16234 | DB06589 | Pazopanib | Inhibitor | Small molecule | Approved |
Tgene | PDGFRA | P16234 | DB08896 | Regorafenib | Inhibitor | Small molecule | Approved |
Tgene | PDGFRA | P16234 | DB08896 | Regorafenib | Inhibitor | Small molecule | Approved |
Tgene | PDGFRA | P16234 | DB08896 | Regorafenib | Inhibitor | Small molecule | Approved |
Tgene | PDGFRA | P16234 | DB09079 | Nintedanib | Inhibitor | Small molecule | Approved |
Tgene | PDGFRA | P16234 | DB09079 | Nintedanib | Inhibitor | Small molecule | Approved |
Tgene | PDGFRA | P16234 | DB09079 | Nintedanib | Inhibitor | Small molecule | Approved |
Tgene | PDGFRA | P16234 | DB10772 | Foreskin keratinocyte (neonatal) | Agonist | Biotech | Approved |
Tgene | PDGFRA | P16234 | DB10772 | Foreskin keratinocyte (neonatal) | Agonist | Biotech | Approved |
Tgene | PDGFRA | P16234 | DB10772 | Foreskin keratinocyte (neonatal) | Agonist | Biotech | Approved |
Tgene | PDGFRA | P16234 | DB14840 | Ripretinib | Inhibitor | Small molecule | Approved |
Tgene | PDGFRA | P16234 | DB14840 | Ripretinib | Inhibitor | Small molecule | Approved |
Tgene | PDGFRA | P16234 | DB14840 | Ripretinib | Inhibitor | Small molecule | Approved |
Tgene | PDGFRA | P16234 | DB00102 | Becaplermin | Biotech | Approved|Investigational | |
Tgene | PDGFRA | P16234 | DB00102 | Becaplermin | Biotech | Approved|Investigational | |
Tgene | PDGFRA | P16234 | DB00102 | Becaplermin | Biotech | Approved|Investigational | |
Tgene | PDGFRA | P16234 | DB01268 | Sunitinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | PDGFRA | P16234 | DB01268 | Sunitinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | PDGFRA | P16234 | DB01268 | Sunitinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | PDGFRA | P16234 | DB06043 | Olaratumab | Antagonist | Biotech | Approved|Investigational |
Tgene | PDGFRA | P16234 | DB06043 | Olaratumab | Antagonist | Biotech | Approved|Investigational |
Tgene | PDGFRA | P16234 | DB06043 | Olaratumab | Antagonist | Biotech | Approved|Investigational |
Tgene | PDGFRA | P16234 | DB06595 | Midostaurin | Antagonist|Inhibitor | Small molecule | Approved|Investigational |
Tgene | PDGFRA | P16234 | DB06595 | Midostaurin | Antagonist|Inhibitor | Small molecule | Approved|Investigational |
Tgene | PDGFRA | P16234 | DB06595 | Midostaurin | Antagonist|Inhibitor | Small molecule | Approved|Investigational |
Tgene | PDGFRA | P16234 | DB08901 | Ponatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | PDGFRA | P16234 | DB08901 | Ponatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | PDGFRA | P16234 | DB08901 | Ponatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | PDGFRA | P16234 | DB09078 | Lenvatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | PDGFRA | P16234 | DB09078 | Lenvatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | PDGFRA | P16234 | DB09078 | Lenvatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | PDGFRA | P16234 | DB12010 | Fostamatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | PDGFRA | P16234 | DB12010 | Fostamatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | PDGFRA | P16234 | DB12010 | Fostamatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | PDGFRA | P16234 | DB12147 | Erdafitinib | Substrate | Small molecule | Approved|Investigational |
Tgene | PDGFRA | P16234 | DB12147 | Erdafitinib | Substrate | Small molecule | Approved|Investigational |
Tgene | PDGFRA | P16234 | DB12147 | Erdafitinib | Substrate | Small molecule | Approved|Investigational |
Top |
Related Diseases for BCR-PDGFRA |
![]() (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Hgene | BCR | C0005586 | Bipolar Disorder | 4 | PSYGENET |
Hgene | BCR | C0023473 | Myeloid Leukemia, Chronic | 3 | CTD_human;ORPHANET |
Hgene | BCR | C0005699 | Blast Phase | 1 | CTD_human |
Hgene | BCR | C0006413 | Burkitt Lymphoma | 1 | ORPHANET |
Hgene | BCR | C0023893 | Liver Cirrhosis, Experimental | 1 | CTD_human |
Hgene | BCR | C0027022 | Myeloproliferative disease | 1 | CTD_human |
Hgene | BCR | C0027540 | Necrosis | 1 | CTD_human |
Hgene | BCR | C0027659 | Neoplasms, Experimental | 1 | CTD_human |
Hgene | BCR | C0041696 | Unipolar Depression | 1 | PSYGENET |
Hgene | BCR | C1269683 | Major Depressive Disorder | 1 | PSYGENET |
Hgene | BCR | C1292769 | Precursor B-cell lymphoblastic leukemia | 1 | ORPHANET |
Tgene | C0238198 | Gastrointestinal Stromal Tumors | 10 | CGI;CLINGEN;CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT | |
Tgene | C3179349 | Gastrointestinal Stromal Sarcoma | 9 | CLINGEN;CTD_human;ORPHANET | |
Tgene | C0346421 | Chronic eosinophilic leukemia | 4 | ORPHANET | |
Tgene | C0206141 | Idiopathic Hypereosinophilic Syndrome | 3 | CTD_human;GENOMICS_ENGLAND | |
Tgene | C0006413 | Burkitt Lymphoma | 2 | ORPHANET | |
Tgene | C0206142 | Eosinophilic leukemia | 2 | CTD_human | |
Tgene | C0206143 | Loeffler's Endocarditis | 2 | CTD_human | |
Tgene | C1292769 | Precursor B-cell lymphoblastic leukemia | 2 | ORPHANET | |
Tgene | C1540912 | Hypereosinophilic syndrome | 2 | CGI;CTD_human | |
Tgene | C0008925 | Cleft Palate | 1 | CTD_human | |
Tgene | C0015923 | Fetal Alcohol Syndrome | 1 | PSYGENET | |
Tgene | C0018801 | Heart failure | 1 | CTD_human | |
Tgene | C0018802 | Congestive heart failure | 1 | CTD_human | |
Tgene | C0023212 | Left-Sided Heart Failure | 1 | CTD_human | |
Tgene | C0023893 | Liver Cirrhosis, Experimental | 1 | CTD_human | |
Tgene | C0024115 | Lung diseases | 1 | CTD_human | |
Tgene | C0025149 | Medulloblastoma | 1 | CTD_human | |
Tgene | C0035238 | Congenital abnormality of respiratory system | 1 | CTD_human | |
Tgene | C0038219 | Status Dysraphicus | 1 | CTD_human | |
Tgene | C0080178 | Spina Bifida | 1 | CTD_human | |
Tgene | C0205833 | Medullomyoblastoma | 1 | CTD_human | |
Tgene | C0206637 | Mesenchymal Chondrosarcoma | 1 | CTD_human | |
Tgene | C0235527 | Heart Failure, Right-Sided | 1 | CTD_human | |
Tgene | C0266508 | Rachischisis | 1 | CTD_human | |
Tgene | C0278510 | Childhood Medulloblastoma | 1 | CTD_human | |
Tgene | C0278876 | Adult Medulloblastoma | 1 | CTD_human | |
Tgene | C0376634 | Craniofacial Abnormalities | 1 | CTD_human | |
Tgene | C0751291 | Desmoplastic Medulloblastoma | 1 | CTD_human | |
Tgene | C1275668 | Melanotic medulloblastoma | 1 | CTD_human | |
Tgene | C1837218 | Cleft palate, isolated | 1 | CTD_human | |
Tgene | C1959583 | Myocardial Failure | 1 | CTD_human | |
Tgene | C1961112 | Heart Decompensation | 1 | CTD_human | |
Tgene | C2718076 | Fetal Mummification | 1 | CTD_human | |
Tgene | C2985290 | Fetal Alcohol Spectrum Disorders | 1 | PSYGENET | |
Tgene | C4545381 | Myeloid and/or lymphoid neoplasm associated with platelet derived growth factor receptor alpha rearrangement | 1 | ORPHANET |